Open Nav

Gila Therapeutics, Inc.

Increase exposure to potential Series B investors

  • Date:Thursday, October 18
  • Time:2:00 PM - 2:15 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Gila is developing breakthrough obesity treatments based on the topical lingual application of natural satiety hormones, which are normally secreted into the bloodstream after we eat to tell us we've had enough. At Gila, we deliver them before you eat so you feel full sooner, eat less & lose weight, with no safety or tolerability issues & no systemic exposure, no absorption into the blood, now demonstrated in mice, rats & dogs at doses up to 10,000x above the therapeutic range. Our patented process exploits the newly described & otherwise unexploited connection between the tongue & the brain, fully activating the satiety response, as strong as a hormone injection or a large meal. We recently completed our phase I clinical trial, fully meeting the safety endpoints while demonstrating a satiety response twice as strong as Saxenda (separate studies, not side-by-side), the leading drug on the market today, an injectable that causes intolerable nausea in 40% of patients.
  • Company
  • Company HQ City:Minneapolis
  • Company HQ Country:United States
  • Company HQ State:Minnesota                  
  • CEO/Top Company Official:Thomas J. Vasicek, Ph.D
  • Year Founded:2014
  • Main Therapeutic Focus:Metabolic Diseases
  • Lead Product in Development :GT-001
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:Gila is a virtual company with a dedicated team of independent consultants who are deeply committed to the project, executing from first funding through phase I on only $4M and in record time, 18 months. We are now poised to start phase II while we raise our series B financing.
  • Previous and Current Investors:Broadview Ventures, iSelect Funds, and many angels
  • Size of Last Investment Round:$5,250,000.00
  • Total Amount Raised to Date, In All Rounds:$5,250,000.00
Thomas Vasicek
Gila Therapeutics, Inc.